Podcasts about nyu langone health

SLPs Meg Lico and Kaitlin Hanley from NYU Langone Health share their story of working with Aaron James, the recipient of what's being called as the first ever full-eye and partial-face transplant. They describe how they worked with James to reach his goals, such as eating solid foods with his family.Central to the story is their collaboration and the interdepartmental communication that made success possible. The SLPs provide details about approaching this unique case, as well as their victories, memorable moments, and the emotions they had along the way.At the end of the conversation, hear from James and his wife Meagan.(This conversation was originally published in February 2024.)Learn More:Swallowing Function After Pioneering Partial Face and Whole Eye Transplant: Clinical InsightsFacing the Unknown: An SLP treated a patient before and after his facial transplant surgery.Changes in Articulatory Control Pre– and Post–Facial Transplant: A Case ReportThe Effects of Lip-Closure Exercise on Lip Strength and Function Following Full Facial Transplantation: A Case ReportTranscript

Dr. Steven Flanagan, a nationally renowned expert in the field of traumatic brain injury (TBI), has worked at the Rusk Rehabilitation Institute at NYU Langone Health since 2008. He serves as the Howard A. Rusk Professor of Rehabilitation Medicine and Chairperson of the Department of Rehabilitation Medicine at NYU Grossman School of Medicine. A former President of the American Academy of Physical Medicine & Rehabilitation (PM&R), he is certified by the American Board of PM&R (Brain Injury Medicine). A graduate of the University of Medicine & Dentistry of New Jersey, he completed his medical residency at Mt. Sinai Medical Center/Cabrini, Rehabilitation. Part 1 The discussion covered the following topics: his involvement at Rusk in patient care, research, and professional organizations; impact of COVID on Rusk; traumatic brain injury biomarkers; and recruitment and retention of health professionals.      

Over the weekend, 45-year-old Mohamed Sabry Soliman was arrested and accused of using a makeshift flamethrower to target Jewish individuals in Boulder, Colorado. This incident follows the recent fatal shooting at a Jewish museum in Washington, D.C. Trey Gowdy, a former federal prosecutor, former South Carolina Congressman, and host of Sunday Night in America, joins to discuss the incident and the alarming rise of antisemitic incidents in the United States. An estimated 7.2 million Americans aged 65 and older now live with Alzheimer's. According to the Alzheimer's Association, one in three older adults dies with some form of dementia. Research surrounding the disease is rapidly evolving, with over 100 potential new treatments in the pipeline. Dr. Joel Salinas, Chief Medical Officer for Isaac Health and clinical associate professor at NYU Langone Health, joins the Rundown to discuss the progress being made in fighting Alzheimer's, including a new blood test that can help detect it early. Plus, commentary from the host of “Tomi Lahren is Fearless on Outkick,”  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Over the weekend, 45-year-old Mohamed Sabry Soliman was arrested and accused of using a makeshift flamethrower to target Jewish individuals in Boulder, Colorado. This incident follows the recent fatal shooting at a Jewish museum in Washington, D.C. Trey Gowdy, a former federal prosecutor, former South Carolina Congressman, and host of Sunday Night in America, joins to discuss the incident and the alarming rise of antisemitic incidents in the United States. An estimated 7.2 million Americans aged 65 and older now live with Alzheimer's. According to the Alzheimer's Association, one in three older adults dies with some form of dementia. Research surrounding the disease is rapidly evolving, with over 100 potential new treatments in the pipeline. Dr. Joel Salinas, Chief Medical Officer for Isaac Health and clinical associate professor at NYU Langone Health, joins the Rundown to discuss the progress being made in fighting Alzheimer's, including a new blood test that can help detect it early. Plus, commentary from the host of “Tomi Lahren is Fearless on Outkick,”  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Over the weekend, 45-year-old Mohamed Sabry Soliman was arrested and accused of using a makeshift flamethrower to target Jewish individuals in Boulder, Colorado. This incident follows the recent fatal shooting at a Jewish museum in Washington, D.C. Trey Gowdy, a former federal prosecutor, former South Carolina Congressman, and host of Sunday Night in America, joins to discuss the incident and the alarming rise of antisemitic incidents in the United States. An estimated 7.2 million Americans aged 65 and older now live with Alzheimer's. According to the Alzheimer's Association, one in three older adults dies with some form of dementia. Research surrounding the disease is rapidly evolving, with over 100 potential new treatments in the pipeline. Dr. Joel Salinas, Chief Medical Officer for Isaac Health and clinical associate professor at NYU Langone Health, joins the Rundown to discuss the progress being made in fighting Alzheimer's, including a new blood test that can help detect it early. Plus, commentary from the host of “Tomi Lahren is Fearless on Outkick,”  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Alfredo Morabia (AJPH) interviews Yi-Ling Tan, Program Manager at NYU Langone Health based in New York City, New York about her APHA 2024 presentation titled “An overview of a community-led process to address problem gambling in the Asian American community.” We discuss the reasons that led her to study problem gambling among Asian Americans, and who were the essential community partners in this work?

Story at-a-glance Nearly 40 million Americans take statins daily, yet these drugs don't fix the root cause of high cholesterol and often cause serious side effects like muscle pain and insulin resistance Dr. Adriana Quinones-Camacho, a cardiologist at NYU Langone Health, recommends lifestyle changes — like eating clean fats, exercising, and losing weight — as first-line treatments before resorting to risky cholesterol-lowering medications Eliminating processed seed oils and consuming whole-food omega-3s from fatty fish (in optimal amounts) will help improve your lipid profile and support natural cholesterol clearance through liver and cell function Excess weight raises low-density lipoprotein (LDL) levels and leads to plaque buildup in arteries; reducing sugar, increasing fiber, and adding daily movement reverses this damage and promotes long-term cardiovascular health Statins are linked to diabetes, cataracts, muscle breakdown, and depleted CoQ10, making lifestyle changes not only safer but also more effective for lasting heart and metabolic health

There's a care model for schizophrenia that actually works—why isn't it everywhere? On this episode, W. Gordon Frankle, MD, MBA, Vice Chair of Psychiatry at NYU Langone Health, shares how his team in Brooklyn is building a new model for treating serious mental illness—one rooted in long-term, relationship-driven, team-based care. From wraparound services to precision psychiatry, this conversation explores what happens when you bring humanity, structure, and innovation to a population too often left behind.Also discussed:The first novel schizophrenia drug in over 50 years (Cobenfy)Why clozapine is underused—and how that may finally changeThe potential of brain imaging and biomarkers in psychiatric treatmentWhat a real community mental health system looks likeWhy trust, not just treatment, is essential for recovery

This episode features Leila Zadeh, DMD, FAGD, who discusses advances in digital technology and the relatively recent incorporation of photogrammetry — a method of approximating a 3D structure using 2D images. She shares how it not only improves the accuracy of capturing implant relationships in a 3D space but also helps streamline the final impression process so that it is significantly faster and easier than traditional analog workflows. This story is the feature of an article in the May issue of AGD Impact. Dr. Zadeh is an advanced restorative dentist at digitalDDS and an adjunct assistant professor at NYU Langone Health's advanced education in general dentistry residency. She also creates educational content for Spear Education.

Dr. Ezra Schwartz (@ezraschwartz10) interviews Dr. Firas Moussa and Mr. Jake Howitt to discuss the IMPROVE-AD Trial, a landmark, multi-institutional study investigating treatment strategies for uncomplicated Type B Aortic Dissection (uTBAD). The IMPROVE-AD Trial is a multicenter randomized trial funded by the NIH/NHLBI that compares thoracic endovascular aortic repair (TEVAR) plus optimal medical therapy (OMT) vs. OMT and surveillance with selective TEVAR in patients with uncomplicated TBAD. The trial aims to address critical gaps in evidence left by prior studies (INSTEAD-XL, ADSORB), with a unique focus on quality of life, cost-effectiveness, and genetic data. Dr. Firas Mussa is a professor and the Chief of Vascular and Endovascular Surgery at McGovern Medical School at UTHealth Houston. He previously served as the Director of the Vascular Surgery Residency and Fellowship programs at NYU Langone Health. Dr. Mussa earned his medical degree from the University of Baghdad, followed by general surgery training at Johns Hopkins University and a vascular surgery fellowship at Baylor College of Medicine. His research focuses on complex aortic pathology, and he serves as the principal investigator of the IMPROVE AD trial. Mr. Jake Howitt is the Community Engagement Co-Chair of the IMPROVE AD trial and a leading patient advocate within the PCORI-funded Aortic Dissection Collaborative. As a survivor of aortic dissection, he is passionate about improving patient-provider communication and raising awareness of hereditary aortic disease. His work emphasizes the importance of education, empathy, and community-building in clinical research and care delivery. Special thank you to Jacob Soucy (@JacobWSoucy). Resources: ·       Treatment of Uncomplicated Type B Aortic Dissection: Optimal Medical Therapy vs TEVAR + Optimal Medical Therapy- https://journals.sagepub.com/doi/10.1177/15385744231184671?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed  ·       INSTEAD Trial - https://pubmed.ncbi.nlm.nih.gov/19996018/ ·       INSTEAD-XL 5-Year Follow-Up - https://pubmed.ncbi.nlm.nih.gov/23922146/ ·       ADSORB Trial - https://pubmed.ncbi.nlm.nih.gov/24962744/ ·       Feasibility of a proposed randomized trial in patients with uncomplicated descending thoracic aortic dissection: Results of worldwide survey - https://pubmed.ncbi.nlm.nih.gov/27823685/ ·       Treatment of AD: Meta-Analysis - https://pubmed.ncbi.nlm.nih.gov/29066151/ ·       TEVAR vs Medical Therapy- https://pubmed.ncbi.nlm.nih.gov/36334259/ ·       IMPROVE AD Trial website - https://improvead.org ·       John Ritter Foundation for Aortic Health - https://johnritterfoundation.org ·       Think Aorta US - https://thinkaorta.us   Follow us @audiblebleeding Learn more about us at https://www.audiblebleeding.com/about-1/ and provide us with your feedback with our listener survey.  *Gore is a financial sponsor of this podcast, which has been independently developed by the presenters and does not constitute medical advice from Gore. Always consult the Instructions for Use (IFU) prior to using any medical device.      

I sit down with Dr Aasma Shaukat, Gastroenterologist and Professor of Population Health, who is also trained in Epidemiology and Clinical Research, and Director of GI Outcomes Research at NYU Langone Health, Grossman School of Medicine.  We talk about progress in healthcare fields including gastroenterology.  We talk microbiome (I compared my digestive tract to the ocean).  We did talk colonoscopy prep in quite a bit of detail.  We also talk about screening rates in the NYC area< C5 and how fortunate we are to work and live in an area that really tries to be inclusive and proactive.  Gastroenterology has incorporated AI tools, so far in polyp detection, but also summarizing patient history and creating a whole picture, which is also helpful in oncology and more.  Note that this was originally recorded just after the New Year in early January.  

How do you help a child with ADHD stay organized, on task, and confident in school? Richard Gallagher, PhD, a child and adolescent psychologist at NYU Langone Health, shares groundbreaking research on organizational skills training for children with ADHD—a behavioral treatment that's changing lives and improving classroom performance. This episode dives into how executive functioning challenges manifest in real life, the strengths (and limits) of technology, and the power of parent training and therapeutic coaching to help children thrive.Dr. Richard Gallagher is Associate Professor in the Department of Child and Adolescent Psychiatry at NYU Grossman School of Medicine, and Director of the Organization Skills Program.

With clinician-informaticist collaboration, enterprise-wide governance, and a deep bench of automation use cases, NYU Langone Health is pushing the boundaries of robotic process automation and agentic AI. When a bot at NYU Langone Health identifies a medication reconciliation gap, it doesn't just log an alert. It initiates a secure chat among the attending physician, quality […] Source: NYU Langone Builds Bot-Powered Playbook for Clinical Transformation on healthsystemcio.com - healthsystemCIO.com is the sole online-only publication dedicated to exclusively and comprehensively serving the information needs of healthcare CIOs.

The Smart 7 is an award winning daily podcast, in association with METRO that gives you everything you need to know in 7 minutes, at 7am, 7 days a week...With over 18 million downloads and consistently charting, including as No. 1 News Podcast on Spotify, we're a trusted source for people every day and the Sunday 7 won a Gold Award as “Best Conversation Starter” in the International Signal Podcast Awards If you're enjoying it, please follow, share, or even post a review, it all helps...Today's episode includes the following guests:Guests Oprah Winfrey - Space Fan and former TV HostEmily Ratajkowski - Actress and Model Will Guyatt - The Smart 7's Tech Guru Dr Ana Angelova-Volpovi - Director of Regenerative Dentistry at Kings College LondonWilliam Curley - Pâtissier Chocolatier Jonathan Parkman - Head of Cocoa, at Marex Mariel Benjamin - Assistant Professor of Allergy and Immunology at the University of Michigan Health Doctor Tania Elliott - Clinical Instructor at NYU Langone Health and spokesperson for the American College of Allergy, Asthma and ImmunologyProfessor Nikku Madhusudhan - Astrophysicist at the University of CambridgeJohan Erlag - Project Manager at SVT Play, Swedish State Broadcaster Contact us over @TheSmart7pod or visit www.thesmart7.com or find out more at www.metro.co.uk This Episode is presented by Mike Wooller, written by Liam Thompson and produced by Daft Doris. Hosted on Acast. See acast.com/privacy for more information.

ADHD isn't just a childhood condition—many adults go undiagnosed for years. Lenard Adler, MD, Director of the Adult ADHD Program at NYU Langone Health, breaks down the nuances of ADHD in adults, the challenges of proper diagnosis, and the latest treatments available. Learn about his research, the screening tools his team has developed, and what's on the horizon for adult ADHD care.

Despite affecting more Americans than diabetes, substance use is often left out of routine medical care. In this episode, NYU Langone Health's Jennifer McNeely, MD—a clinician investigator, primary care and addiction medicine physician—explains why that must change. From the surprising history behind addiction's exclusion from mainstream medicine to the innovative screening tools shaping the future of care, this conversation is a must-listen for anyone interested in addiction care and healthcare policy.Jennifer McNeely, MD, is an Associate Professor of Medicine and Population Health at NYU Grossman School of Medicine and co-director of the Section on Tobacco, Alcohol, and Drug Use.

In this episode of the Dr. Geo Prostate Podcast, Dr. Geo welcomes Dr. Alberto Vargas, Vice Chair of Oncologic Imaging at NYU Langone Health and expert in prostate cancer imaging.They dive deep into the evolving world of diagnostic tools—MRI, PET, CT, and PSMA scans—and how these technologies help detect, monitor, and guide treatment for prostate cancer. Dr. Vargas explains the difference between imaging modalities, when to use them, and how PSMA PET scans are changing the game in identifying recurrent and metastatic disease earlier than ever before.Key topics covered:MRI vs. PET vs. CT: what each scan shows and when it matters mostThe rise of PSMA PET for finding prostate cancer at extremely low PSA levelsWhy not all PET scans are the same, and how tracers like FDG, Axumin, and PSMA workThe potential future of prostate cancer diagnosis: fewer biopsies, more imagingLimitations, false positives, and how imaging results are interpretedThe role of imaging in both first-time diagnosis and recurrenceWhether you're a patient, caregiver, or clinician, this episode offers valuable insight into how imaging helps guide smart, proactive decisions in prostate cancer care.----------------Thank you to our partnersThe ProLon 5-Day Fasting Mimicking Diet is a plant-based meal program designed to provide fasting benefits while allowing food intake. Developed by Dr. Valter Longo, it supports cellular renewal, fat loss, and metabolic health through low-calorie, pre-packaged meals that maintain the body in a fasting state.Special Offer: Thank you for listening, you can purchase the ProLon kit for just $148 by using this link.We'd also like to thank our partner AG1 by Athletic Greens. AG1 contains 75 high-quality vitamins, minerals, whole-food sourced ingredients, probiotics, and adaptogens to help you start your day right. This special blend of ingredients supports your gut health, nervous system, immune system, energy, recovery, focus, and aging. All the essentials in one scoop. Enjoy AG1 by Athletic Greens.----------------Thanks for listening to this week's episode. Subscribe to The Dr. Geo YouTube Channel to get more content like this and learn how you can live better with age.You can also listen to this episode and future episodes of the Dr. Geo Podcast by clicking HERE.----------------Follow Dr. Geo on social media. Facebook, Instagram Click here to become a member of Dr. Geo's Health Community.Improve your urological health with Dr. Geo's formulated supplement lines:XY Wellness for Prostate cancer lifestyle and nutrition: Mr. Happy Nutraceutical Supplements for prostate health and male optimal living.You can also check out Dr. Geo's online dispensary for other supplement recommendations Dr. Geo's Supplement...

In this episode of the Dr. Geo Prostate Podcast, Dr. Geo welcomes Dr. Alberto Vargas, Vice Chair of Oncologic Imaging at NYU Langone Health and expert in prostate cancer imaging.They dive deep into the evolving world of diagnostic tools—MRI, PET, CT, and PSMA scans—and how these technologies help detect, monitor, and guide treatment for prostate cancer. Dr. Vargas explains the difference between imaging modalities, when to use them, and how PSMA PET scans are changing the game in identifying recurrent and metastatic disease earlier than ever before.Key topics covered:MRI vs. PET vs. CT: what each scan shows and when it matters mostThe rise of PSMA PET for finding prostate cancer at extremely low PSA levelsWhy not all PET scans are the same, and how tracers like FDG, Axumin, and PSMA workThe potential future of prostate cancer diagnosis: fewer biopsies, more imagingLimitations, false positives, and how imaging results are interpretedThe role of imaging in both first-time diagnosis and recurrenceWhether you're a patient, caregiver, or clinician, this episode offers valuable insight into how imaging helps guide smart, proactive decisions in prostate cancer care.----------------Thank you to our partnersThe ProLon 5-Day Fasting Mimicking Diet is a plant-based meal program designed to provide fasting benefits while allowing food intake. Developed by Dr. Valter Longo, it supports cellular renewal, fat loss, and metabolic health through low-calorie, pre-packaged meals that maintain the body in a fasting state.Special Offer: Thank you for listening, you can purchase the ProLon kit for just $148 by using this link.We'd also like to thank our partner AG1 by Athletic Greens. AG1 contains 75 high-quality vitamins, minerals, whole-food sourced ingredients, probiotics, and adaptogens to help you start your day right. This special blend of ingredients supports your gut health, nervous system, immune system, energy, recovery, focus, and aging. All the essentials in one scoop. Enjoy AG1 by Athletic Greens.----------------Thanks for listening to this week's episode. Subscribe to The Dr. Geo YouTube Channel to get more content like this and learn how you can live better with age.You can also listen to this episode and future episodes of the Dr. Geo Podcast by clicking HERE.----------------Follow Dr. Geo on social media. Facebook, Instagram Click here to become a member of Dr. Geo's Health Community.Improve your urological health with Dr. Geo's formulated supplement lines:XY Wellness for Prostate cancer lifestyle and nutrition: Mr. Happy Nutraceutical Supplements for prostate health and male optimal living.You can also check out Dr. Geo's online dispensary for other supplement recommendations

Lupus nephritis, affecting nearly half of lupus patients, can cause severe kidney damage. Traditionally, high-dose glucocorticoids (~1 mg per kg prednisone) have been used despite significant side effects. In this episode, host Anna Wolska speaks with Dr. Amit Saxena, a rheumatologist and Associate Professor at NYU Langone Health, about his recent research on the use of glucocorticoids in treating kidney disease in lupus. His study pooled standard-of-care arms from several major clinical trials to compare the efficacy and safety of lower versus higher oral glucocorticoid doses—administered after an initial IV steroid pulse—in treating lupus nephritis.   Read the article published in LSM - https://doi.org/10.1136/lupus-2024-001351

Dr. Vamsi Velcheti and Dr. Charu Aggarwal discuss the evolution of ctDNA as a critical tool in precision oncology and its implications for lung cancer management, including its potential role in the early-stage setting. TRANSCRIPT Dr. Vamsi Velcheti: Hello. I am Dr. Vamsi Velcheti, your guest host for the ASCO Daily News Podcast today. I am a professor of medicine and director of thoracic medical oncology at the Perlmutter Cancer Center at NYU Langone Health.  The management of small cell lung cancer has rapidly evolved over the past few decades, and today, molecular testing and biomarker testing for lung cancer are absolutely critical in terms of designing treatment options for our patients with metastatic non-small cell lung cancer. Today, I'm delighted to be joined by Dr. Charu Aggarwal for a discussion on ctDNA (circulating tumor DNA) and the role of ctDNA in lung cancer management. Dr. Aggarwal is the Leslye Heisler Professor of Lung Cancer Excellence and section chief of thoracic and head and neck oncology at University of Pennsylvania Abramson Cancer Center.  You'll find our full disclosures in the transcript of that episode.  Dr. Agrawal, it's great to have you on the podcast today. Thank you for being here. Dr. Charu Aggarwal: Thank you for having me. Dr. Vamsi Velcheti: Let's start off with setting the stage for ctDNA technology. These technologies have rapidly evolved from experimental conceptual stage to essential clinical tools for day-to-day clinical practice. Could you briefly discuss how recent advancements in ctDNA technologies are shaping our approach to precision medicine, especially in lung cancer? Dr. Charu Aggarwal: Absolutely. And you know, I think we need to just level set a little bit. What exactly is circulating tumor DNA? This is a way to assess exactly that. Every tumor sheds little pieces of tumor-derived DNA into the bloodstream, and this occurs in a variety of solid tumors. But now we have the technology to be able to derive this DNA that's actually being shed from the tumor into the bloodstream, these minute fragments of DNA, take them out, amplify them and sequence them with a variety of different mechanisms. They can be DNA sequencing alone, they can be DNA and RNA sequencing, they can be whole transcriptome sequencing. The technology, as you rightly pointed out, Dr. Velcheti, has significantly improved from just being able to look at circulating tumor DNA to now being able to amplify it, sequence it, and use it to offer personalized therapy. I think lung cancer is definitely the poster child for such an approach as we have a lot of data that has shown clinical utility and validity of being able to use circulating tumor DNA next-generation gene sequencing to guide therapy. Dr. Vamsi Velcheti: There have been so many technological leaps. It's really impressive how far we've come to advance these sequencing platforms. Recent advances with AI and machine learning are also playing important roles in interpreting ctDNA data. How are these computational advances really enhancing clinical decision-making in day-to-day clinical practice? Dr. Charu Aggarwal: I think while we have firmly established the role of ctDNA in the management of patients with metastatic lung cancer, some of the approaches that you talked about are still experimental. So let me backtrack a little bit and set the stage for how we use ctDNA in clinical practice right now. I think most patients, when they come in with a new diagnosis of stage IV lung cancer, we want to test for biomarkers. And this should actually be the established standard. Now included in the NCCN guidelines and actually also international guidelines, is to consider using blood-based testing or plasma-based testing to look for biomarkers, not just tissue-based testing which had been our historical standard, but to use these plasma guided approaches to identify the seven to nine biomarkers that may be truly implicated in either first- or second-line therapy that are called as your immediately actionable mutations.  What you're talking about is AI computational methods. I think there's a lot of excitement about how we can use genomic signatures that are derived from either tissue or ctDNA-based biomarker testing, combine it with radiomic features, combine it with histologic features, look at H & E patterns, use AI algorithmic learning to be able to actually predict recurrence scores, or can we actually come up with predictive signatures that may be extremely helpful?  So, I think some of the techniques and technologies that you're talking about are incoming. They are provocative. I think they're very exciting, but very early. Dr. Vamsi Velcheti: I think it's really amazing how many advances we have with these platforms. You know, the challenge really is the significant gap in terms of uptake of molecular testing. Even today, in 2025, there are significant gaps in terms of all metastatic lung cancer patients being tested for all biomarkers.  So, why do you think there's such a challenge in testing patients with lung cancer? In most academic practices, we try to achieve 100% testing for all our patients, but we know from recent studies that that's not the case across the country. What do you think the gaps are? Dr. Charu Aggarwal: Biomarker testing is so essential, like you pointed out, for us to be able to guide the right therapy for our patients. And we see this in our practice every day as you and I see patients with lung cancer, that a large proportion of our patients either don't get tested or they start therapy before their test results come back. So, I think this is a real problem.  However, to add some optimism to this problem, I do think that we are making a move in the right direction. So, four or five years ago, there was a lot of data being presented at national meetings, including ones from the American Society of Clinical Oncology, where we saw that, nationally, the rates of biomarker testing were probably in the rate of 40 to 50%. However, now with the availability of both tissue and plasma, I do think that the rates of biomarker testing are increasing. And if you were to survey a sample or even perform retrospective data research, I believe that the number is closer to 70% of all patients with metastatic non-small cell lung cancer.  And you know, you asked why is it not 100%? I think there are many reasons. I think the number one reason is tissue availability. Many times, the biopsies are small, or the tumor is very necrotic. So, either the tissue quantity itself is small, or the tissue quantity is insufficient to perform gene sequencing. And that's exactly where plasma comes in. When you don't have tissue availability, we have shown, as have others, that you can use plasma effectively to increase the proportion of patients who are not only tested but also receive the right therapy. I think there are also other barriers, including inertia. You know, I think this is both patient and physician inertia, where patients want to get started quickly, they don't want to wait. Physicians are very busy and sometimes want to be able to deliver treatment as soon as possible. We have seen there are some institutional barriers. Not every institution has in-house gene sequencing testing. So how do you really operationalize, send out these tests in a fast, efficient manner so that you get results back? Is it a pathologist who sends out the test? Is it the medical oncologist? Is it the pulmonologist or the interventionalist? I think there is this need to develop reflex testing mechanisms which some institutions do really well and some don't. And then finally, there are financial implications as well. How do we do this in a most cost-efficient fashion?  So there are many barriers, but I'm happy to say that we are making a move in the right direction as we are understanding that it's important to do it, it's easy to do it maybe with a value add of plasma, and finally, as you said, you know, as these technologies become more available, they're actually getting more cost-effective. Dr. Vamsi Velcheti: Dr. Aggarwal, you've been at the cutting edge of these advanced platforms and testing. So, what do you do in UPenn? How do you handle all these barriers and what is your workflow for patients in University of Pennsylvania? Dr. Charu Aggarwal: One of the things that I mentioned to you was there may be institutional barriers when it comes to gene sequencing. So, we actually, several years ago now, instituted a very robust reflex testing paradigm where almost all of our patients, regardless of stage, with a non-squamous non-small cell lung cancer diagnosis, would automatically be reflexively sent to our molecular pathology lab where they would get gene sequencing both for the DNA as well as with an RNA fusion-based platform. And the reason we did this was because we wanted to expedite and reduce the turnaround time. We also wanted to ensure that we were not just doing DNA testing, which I think is really important for our listeners here. There are many fusions as well as certain skipping mutations like MET exon 14 that may be missed on DNA testing alone. So, it's really incredibly important to run both DNA and RNA samples.  So, we do this routinely, and based on our research and others, what we also do routinely is that we send concurrent tissue and liquid biopsies or plasma MGS testing upon initial diagnosis. For example, if a patient comes in with a diagnosis of stage IV non-small cell lung cancer, their tissue might already be at my molecular pathology lab based on the reflex mechanism that I just described to you. But upon their initial meeting with me, we will send off plasma. And I will tell you this, that Penn is not just one institution, right? We have a large network of sites. And as part of my research, one of the things that we wanted to do was implement wide scale means to improve biomarker testing. And we have done this with the use of technology like you mentioned, Dr. Velcheti: How can we actually use AI? How can we leverage our electronic medical record to identify these patients? So, we have a nudge-based mechanism which actually facilitates the pending of orders for biomarker testing for patients with new diagnosis of metastatic non-small cell lung cancer. And we are looking at our rates of biomarker testing but also rates of completion of biomarker testing before first-line therapy started. So many of our participating sites are clusters for our randomized control trial to increase molecular testing. And I'm really excited about the fact that we're able to implement it not just at our main satellite, downtown Penn Hospital, but also across our community. Dr. Vamsi Velcheti: I think that's great. Thank you so much for those insights, Dr. Aggarwal. I think it's so important because having the best technology is just not enough. I think implementation science is actually a real thing. And I think we need to all learn from each other, advance these things.  So, I want to ask you about the new emerging paradigm in terms of using ctDNA. Of course, in the metastatic setting, we've been using ctDNA for molecular profiling for a while now. But the recent data around monitoring early-stage disease, especially post-operative monitoring, is an exciting area. There are a lot of opportunities there. Could you please talk us through the emerging data in lung cancer and how do we incorporate ctDNA-based monitoring MRD or should we even do that right now? Is the data ripe enough for us to kind of deploy this in a clinical setting? Dr. Charu Aggarwal: I think using ctDNA in the early-stage setting is our next frontier in lung cancer. I think naturally we have been able to successfully deploy this in the stage 4 setting. It made a meaningful difference in the lives of our patients, and we are a little bit behind the A ball in terms of how MRD is used in lung cancer. Because, you know, colorectal cancer has already done large-randomized trials based on ctDNA and MRD. It's routinely used in hematological malignancy. So, it makes sense that we should start to use it.  However, when I say this, I say this with excitement, but also a little bit of gentle caution saying that we actually don't quite have the prospective randomized data just yet on how to deploy. Yes, intuitively we would say that if you detect ctDNA and MRD, that patient is at higher risk. So, we identify that, but we actually don't know what to do with the second part of that information once you identify a patient with high risk. Are there other techniques that we can then come in with or other drugs that we can come in with to modify that risk? And that's the thing that I think we don't have right now. The other thing that we don't have right now is the timing of the assay, when to use it. Is it to be tested in the pre-op setting? Is the post-op test the best timing, or is it monitoring and dynamics of ctDNA that are most important? And the third thing I will say in terms of precautionary cause is that we don't know which test just yet. There are actually a few commercially available tests out in the market right now. We know about them and I'm sure our community colleagues know about them. Some of them even have Medicare approval. However, many of these tests are currently tissue informed. We don't have tissue uninformed tests. And what does that mean? Tissue uninformed means that you actually take a piece of tumor tissue, you sequence that tumor and based on the gene profile of that tumor, you actually design a panel that can then be used to track the mutations in the blood-based pack. This requires, as the name implies, a tumor. So can this be used in the pre-op setting is a large question. Because coming back to the idea of tissue availability, you and I both know that when we get FNAS and we use it for PDL-1 testing and we use it for gene sequencing, there often isn't enough tissue left for us to then either do whole genome sequencing or even whole transcriptome sequencing, which may be required to build some of these assays.  I think the future lies in this idea of tumor uninformed assays because if we could go to a blood only or a plasma only approach using novel signatures like proteomics or methylation, I think that's where the future is. But we're still a little bit early in the discovery stages of those, as well as to come are the validation stages so that we can be confident that these blood-only assays may actually give us an answer.  So, with those three cautionary notes, I would say that optimism is still very high. I think ctDNA MRD is the right place to think about. We need to do this for our patients to better identify high-risk patients and to think about means to escalate treatment for them. Dr. Vamsi Velcheti: Yeah, I completely agree, and I think with all the changes and evolution of treatments in the management of early-stage lung cancer now with neoadjuvant and adjuvant, there's really a need for an escalation and de-escalation of therapies post-operatively. And I think it's a huge opportunity. I think we all could learn from our colorectal colleagues. I think they've done a really good job at actually doing prospective trials in this setting. I think we're kind of a little behind here.  Dr. Charu Aggarwal: I think in the metastatic setting there are ongoing trials to look at this exact question. How do you choose an appropriate first-line therapy, a monitor ctDNA at the six-week trial? It's being evaluated in a trial called the “Shedders” trial, where if patients are still ctDNA positive at six weeks, then you can escalate treatment because they haven't “cleared” their ctDNA. There has been a lot of research that has shown that lack of ctDNA clearance in the metastatic setting may be a poor prognostic factor. We and others have shown that if you do clear your ctDNA or if you have a reduction in ctDNA load overall, that that is directly related to both an improved progression-free survival and overall survival. This has been shown with both tissue informed and uninformed assays. So I think it's very clear that yes, you can track it. I think the question is: Can you apply that data to the early-stage setting? And that's an open research question. A lot of groups are looking at that and I think it's completely reasonable, especially to determine duration of therapy, to determine optimal timing, optimal timing of scans even. And I think these are just such interesting questions that will be answered in the future. Dr. Vamsi Velcheti: And also like a kind of early detection of resistance patterns that might inform early initiation of combination strategies. And I think it's a lot of opportunities I think yet to be explored. A lot of exciting things to come and I'm sure we'll kind of see more and more data in the next few years.  Dr. Aggarwal, thank you so much for sharing your fantastic insights today on the ASCO Daily News Podcast. It's been a pleasure to have you on the podcast today. Hope to see you at ASCO. Dr. Charu Aggarwal: Thank you so much. This was great and I remain so excited by all of the possibilities to improve outcomes for our patients. Dr. Vamsi Velcheti: Thank you to all the listeners for your time today. If you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcast. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Follow today's speakers:  Dr. Vamsidhar Velcheti  @VamsiVelcheti  @vamsivelcheti.bsky.social Dr. Charu Aggarwal @CharuAggarwalMD   Follow ASCO on social media:  @ASCO on X (formerly Twitter)  ASCO on Bluesky ASCO on Facebook  ASCO on LinkedIn    Disclosures: Dr. Vamsidhar Velcheti:  Honoraria: Glavanize Therapeutics Consulting or Advisory Role: Bristol-Myers Squibb, Merck, AstraZeneca/MedImmune, GSK, Amgen, Taiho Oncology, Novocure, Takeda, Janssen Oncology, Picture Health, Regeneron Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline  Dr. Charu Aggarwal: Consulting or Advisory Role: AstraZeneca, Daiichi Sankyo/AstraZeneca, Regeneron/Sanofi, Pfizer, Boehringer Ingelheim, Takeda, Arcus Biosciences, Gilead Sciences, Novocure, Abbvie Speakers' Bureau: AstraZeneca (an immediate family member) Research Funding (Inst): Merck Sharp & Dohme, AstraZeneca/MedImmune, Daiichi Sankyo/AstraZeneca, Lilly@Loxo, Candel Therapeutics  

Today, I have the pleasure of connecting with Dr. Sue Varma. Dr. Varma is a privately-practicing board-certified psychiatrist and a Clinical Assistant Professor of Psychiatry at New York University. She is a nationally acclaimed keynote speaker, medical contributor, media consultant, and advisor to leading television networks and programs. In our discussion today, we examine the impact of shared life experiences like 9/11 and the pandemic, exploring the role of PTSD and the effects of practical optimism, self-care, and self-reliance. We discuss optimism, its inheritability, and the significance of milestones for women, including transitioning from high school to college, navigating midlife, and addressing feelings of loneliness. We also look into purpose and compassion, the complexities of processing emotions, the challenges of the perfectionism façade, the role of trauma, ACE scores, autoimmunity, and the benefits of mindfulness and meditation.  Stay tuned for more! IN THIS EPISODE YOU WILL LEARN: Dr. Varma discusses the collective sense of grief, fear, connection, and empathy after 9/11 and the pandemic The importance of optimism and resilience when dealing with tragedy How Dr. Varma helps her patients identify their blind spots and other areas for improvement in their lives How perimenopause can bring about a sexual awakening and increased desire for intimacy but also loneliness and dissatisfaction in relationships Why friendships are essential for our well-being Why do we need to invest in different types of connections and relationships? The critical importance of finding purpose in life  How unprocessed emotions affect our mental and physical well-being How trauma impacts mental health Some practical tips for incorporating mindfulness into daily life  The benefits of meditation Bio: Dr. Sue Varma is a board-certified psychiatrist in private practice and a Clinical Assistant Professor of Psychiatry at New York University (NYU) Langone Health. She is a Distinguished Fellow of the American Psychiatric Association. Dr. Varma was the first medical director and attending psychiatrist at the World Trade Center Mental Health Program at NYU Langone Health, treating civilians and first responders in the aftermath of 9/11. Dr. Varma is a nationally acclaimed keynote speaker, medical contributor, media advisor, and consultant to major networks and shows. She regularly appears on the Today Show, Nightly News, CBS Mornings, and Good Morning America and is frequently interviewed by Time, Washington Post, NPR, and beyond. Dr. Varma is the recipient of numerous prestigious awards for her ground-breaking efforts in mental health education and advocacy, including a Sharecare Emmy. Her forthcoming book, “Practical Optimism,” is eagerly anticipated worldwide, with translations in several languages. Connect with Cynthia Thurlow Follow on Twitter Instagram LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Connect with Dr. Sue Varma On her website Instagram Facebook Twitter LinkedIn Dr. Varma's book, Practical Optimism:  The Art, Science, and Practice of Exceptional Well-Being

March 13, 2025: Sarah Richardson and Kate Gamble discuss NYU Langone Health's groundbreaking integration of Amazon One palm scanning technology for patient check-ins. They explore how this contactless biometric system is streamlining the authentication process with six nines accuracy while maintaining HIPAA compliance. Subscribe: This Week Health Twitter: This Week Health LinkedIn: This Week Health Donate: Alex's Lemonade Stand: Foundation for Childhood Cancer

Many patients with epilepsy are unable to acheive optimal seizure control with medical therapy. Palliative surgical procedures, neurostimulation devices, and other nonpharmalogical treatments can lead to a meaningful reduction in seizures and improved outcomes. In this episode, Teshamae Monteith, MD FAAN, speaks with Daniel Friedman, MD, MSc, author of the article “Surgical Treatments, Devices, and Nonmedical Management of Epilepsy,” in the Continuum® February 2025 Epilepsy issue. Dr. Montieth is a Continuum® Audio interviewer and an associate editor of Continuum® Audio and an associate professor of clinical neurology at the University of Miami Miller School of Medicine in Miami, Florida. Dr. Friedman is a professor (clinical) of neurology at NYU Grossman School of Medicine and Director of NYU Langone Comprehensive Epilepsy Center at NYU Langone Health in New York, New York. Additional Resources Read the article: Surgical Treatments, Devices, and Nonmedical Management of Epilepsy Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @headacheMD Guest: @dfriedman36  Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum Journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Monteith: This is Dr Teshamae Monteith. Today, I'm interviewing Dr Daniel Friedman about his article on surgical treatments, devices, tools, and non-medication management of epilepsy, which appears in the February 2025 Continuum issue on epilepsy. Welcome to the podcast. How are you? Dr Friedman: I'm well, how are you? Dr Monteith: Thank you for your article. Dr Friedman: Thank you for the opportunity to talk today. Dr Monteith: Why don't you introduce yourself? Dr Friedman: So yeah, so I'm Dan Friedman. I am a professor of neurology here at NYU Grossman School of Medicine and I am the director of the NYU Comprehensive Epilepsy Center. I'm primarily an adult neurologist and I treat teens and adults with hard- difficult-to-treat epilepsy, including surgical treatments for epilepsy. Dr Monteith: And I know you see a lot of patients because I did my residency there. And so, when you graduate, you get a lot of it, like I think many, many residents. What inspired you to choose epilepsy as a profession? Dr Friedman: I came to neurology through my interest in neuroscience. I was a neuroscience undergraduate. I was very interested in the brain and brain function. Particularly, I was interested in how neurons communicate and organize to entrain and rhythms and that encode information. And through that interest and through my experiences in the laboratory, I actually became interested in how they do that in pathological circumstances like seizures. And so, I started reading about epilepsy, and then when I started seeing patients with epilepsy, you know, I decided this is the specialty for me for a lot of reasons. One is it combines inpatient and outpatient care. You get to establish long-term relationships with patients. For many of my patients, I'm probably the doctor that they see most often. You see people across the lifespan. And what I'm going to talk about today is for some people, you actually get to cure their disease, which at the time I was coming into neurology was something pretty rare. Dr Monteith: Yeah, that's great. Why don't you tell us, what were you thinking when you started writing the article? What did you set out to do? Dr Friedman: What I really wanted to do is to educate neurologists out there about the options that they have for their patients with epilepsy, especially those with difficult-to-treat or drug-resistant epilepsy, and give them the tools to communicate those options. Especially for them to understand the rationale, why we choose the interventions that we do as epileptologists, how to appropriately refer patients and have them be partners in that discussion with patients and families. One of the things that we have known for a long time is that the time to referral for things like epilepsy surgery is too long. You know, the average patient with drug resistant epilepsy who undergoes epilepsy surgery waits about twenty years. And for patients who could have curative therapy, you know, become seizure free, that's a lot of life years lost. If we can get patients to that potentially life-altering therapy earlier, that'd be great. Dr Monteith: Yeah, that is really impactful as you think about it. So why don't you tell us what the essential points of your article? Dr Friedman: The central point of my article is really that when patients have drug-resistant epilepsy, which means that our available anti-seizure medicines are not controlling their seizures to the degree that they need, there are other treatment options. Some of those are what we call curative, which means that they could stop their seizures entirely; and some of them are palliative, they could reduce the frequency or severity of seizures and improve quality of life and other outcomes. The other thing that I wanted to highlight was, in addition to these types of therapies, there are other tools we have at our disposal that can improve the quality of life and safety of our patients with epilepsy, including devices for seizure monitoring. Dr Monteith: And how do you define drug-resistant epilepsy? I feel like that could be a moving target. Dr Friedman: The International League Against Epilepsy actually set out to define it about a decade ago, and they defined it as patients who fail at least two appropriately selected anti-seizure medicines due to lack of efficacy. Then they're still having ongoing seizures. What does that mean? So, that means that the medicine that was chosen was appropriate for the type of seizures that they have, whether it's focal or generalized, and that it didn't work because of a lack of efficacy and not because of side effects. And we know from multiple studies that once patients fail two medications, the likelihood that the third, fourth, fifth, etcetera, medicine will control their seizures becomes smaller and smaller. It's not impossible, but the rates fall below five percent. And so we call those patients drug-resistant. Dr Monteith: So, it sounds like despite newer therapies, really things haven't changed in ten years. Dr Friedman: Yeah, unfortunately, at least when the concept was first investigated back in 2000 by Quan and Brody, they found that a third of patients were drug-resistant. When they went back in the mid-2010s to relook at these patients, despite the introduction of many new medications, the rate of patients who were drug-resistant was essentially unchanged. There may be therapies that are emerging or in development that may have better odds, but right now we don't really understand what makes people drug resistant and how we can target that. Dr Monteith: But you do raise a good point that this is about efficacy and not tolerability. And at least for some of the newer medications, they're better tolerated. If you stop the medicine because you had some side effect, that might change how that person has classified better-tolerated treatments. Dr Friedman: It's true. And better-tolerated treatments, you can potentially use higher doses. One of the things that is not in the definition of drug-resistant epilepsy, but as a practicing neurologist, we all know, is that the patients have to take the medicine for it to be effective. And unfortunately, they have to take it every day. And if the medicine makes them feel bad, they may choose not to take it, present to you as drug-resistant, when in reality they may be drug-sensitive if you got them on medicine that doesn't make them feel bad. Dr Monteith: So why don't we talk about patients that are ideal candidates for epilepsy surgery? Dr Friedman: The ideal candidates for epilepsy surgery… and I'll start by talking about curative epilepsy surgery, where the goal of the surgery is to make patients seizure-free. The best candidates are patients who have lesional epilepsy, meaning that there is a visible MRI abnormality like a focal cortical dysplasia, hippocampus sclerosis, cavernoma in a part of the brain that is safe to resect, non-eloquent, and where you can safely perform a wide margin of resection around that lesion. It helps if they have few or no generalized tonic-clonic seizures and a shorter duration of epilepsy. So the ideal patient, the patient that if they came to my office, I would say you should get surgery right now, are patients with non-dominant temporal lobe epilepsy of a few years' duration. So as soon as they've shown that they're not responding to two medicines, those are the ideal patients to say, you would have the most benefit and the least risk from epilepsy surgery. We know from studies that patients with temporal lobe epilepsy do a little better with surgery. We know patients who have a visible lesion on MRI do better with epilepsy surgery. We know that patients who have infrequent secondarily generalized seizures do better. But all patients with drug-resistant epilepsy should be considered for some form of surgery because even if they're not candidates for a curative surgery, there may be some palliative options, whether it's surgical resections that lessen the severity of their seizures or neurostimulation devices that reduce the frequency and severity of seizures. Ideal candidates, the ones that you would push through sooner rather than later, are those who have the likelihood of the best outcomes and the least risk of neurocognitive decline. Dr Monteith: So, you mentioned that there may be other candidates that still benefit, although maybe not ideal. You mentioned neuromodulation. What other interventions are available? Dr Friedman: For patients who are not candidates for resective surgery, there are several neurostimulation options. There's vagus nerve stimulation, which has been around the longest. It is a device that is implanted in- under the skin near the clavicle and has a lead that goes to the left vagus nerve and delivers stimulation, electrical stimulation to the nerve. For reasons we don't fully understand, it can reduce the both the frequency and severity of seizures. Seldom does it make people seizure free, but the reduction in seizure frequency for many patients is associated with improved quality of life, reduced risk of injury, and even reduced rates of SUDEP. We also have two intracranial neurostimulation devices we use for epilepsy. One is the responsive neurostimulator. So, this is a device that- it has leads that are implanted directly into the seizure focus and sense electrocortical brain activity and deliver electrical stimulation to attempt to abort abnormal brain activity. So functioning kind of like a cardiac defibrillator for the heart, but for seizures in the brain. And because these devices have two leads, they can be used to treat people with more than one seizure focus---so up to two---or be used in patients who are not candidates for resection because their seizure focus is in language cortex, motor cortex, things that would be unable to resect. And the RNS has somewhat better efficacy in terms of percent reduction in seizures compared to the VNS, but obviously because it's an intracranial device, it's also a little riskier. It has more potential for neurosurgical adverse effects. There's also a deep brain stimulator for epilepsies, the same exact device that we use to treat movement disorders. We can implant in the thalamus, in either the anterior nucleus of the thalamus or now, for some patients, into the central median nucleus of the thalamus, and deliver open loop stimulation to treat epilepsy and reduce the frequency and severity of seizures as well. Unlike the RNS, you don't have to localize the seizure focus, so you don't need to know exactly where the seizures are coming from. And you could treat patients with multifocal epilepsy with seizures coming from more than two locations or even generalized seizures. Dr Monteith: So, it sounds like there are a lot of options available to patients. I think one of the things I find challenging is when we have patients that may have some cognitive dysfunction, especially in the hospital, and they've had some seizures that are very obvious, but then there are these, maybe, events that you wonder are seizures. So, what is the utility of some of these seizure detection devices? Dr Friedman: The development of seizure detection devices started out primarily with the observation that a majority of cases of sudden unexpected death and epilepsy, or SUDEP, occurred following tonic-clonic seizures. And there was a need to be able to monitor for convulsive seizures, especially that occur at night when people were otherwise unattended. And so, the first generation of devices that were developed came on the market, essentially detected convulsive seizures, and they alerted caregivers nearby who are able to come to the bedside, provide basic seizure first aid, turn people on the side. And theoretically all this---this hasn't been shown in studies---prevents SUDEP. And so, the ones that are currently available on the market are focused on the detection of convulsive seizures, mostly generalized tonic-clonic seizures, but some devices can also detect other seizures with very prominent motor components. What we don't have yet available to us, and what people are working on, are devices that detect nonconvulsive seizures. We know that patients who have focal impaired aware seizures are often amnestic for their seizures. They don't know they had a seizure if family members aren't there to observe them. They may never report them, which makes treating these patients very difficult. How do you quantify disease burden in your headache patients, for instance? You say, how many headache days did you have since we last met in the clinic? Your patients will be able to report on their calendar, this many days. Well, imagine if the patients had no awareness of whether or not they had a headache day. You wouldn't know if your therapy is working or not. In epilepsy, we need those types of devices which can tell us whether patients are having seizures they're unaware of, and that may be more subtle than convulsions. Dr Monteith: Oh, that'd be great for headache, too. You just gave me an idea, but that's the next podcast. So, you mentioned SUDEP, really important. How good are surgical interventions at reducing what we would think the prevalence of SUDEP? Dr Friedman: For me that is one of the primary motivations for epilepsy surgery in patients who are drug-resistant, because we know that if patients who are candidates for epilepsy surgery have high SUDEP rates. Estimates range from six to nine per thousand patients per year. If surgery is successful, their mortality rates go down to the general population level. It literally can be lifesaving for some patients, especially when you're talking about curative epilepsy surgery. But we also know that the biggest driver for SUDEP risk is tonic-clonic seizures and the frequency of those tonic-clonic seizures. So even our palliative interventions, which can reduce the frequency and severity of seizures, may also reduce the risk of SUDEP. So, we know in study- observational studies of patients with VNS and with RNS, for instance, the rates of SUDEP in patients treated with those devices are lower than expected for the drug-resistant epilepsy population. Dr Monteith: Let's talk a little bit about some of these prediction models. And you have a lot of great work in your article, so I don't want to get into all the details, but how do you use that in the real world? Do you communicate that with patients? How do you approach these prediction factors? Dr Friedman: There are two places where, I think, clinical prediction tools for epilepsy surgery have a role. One is, for me, in my clinic where I'm talking to patients about the risks and benefits for surgery, right? You want to be able to accurately communicate the likelihood that the surgery is going to give you the desired outcome. So patients and their families can make educated decisions, be weighing the risks and benefits. I think it's important to be realistic with patients because surgery, like- you know, any surgery is not without risk, both acute risks and long-term risks. You're removing part of the brain, and, you know, every part of the brain is important. That's where I use prediction tools. But I think it's also important for the general neurologist, especially trying to triage which patients you are going to be aggressive with referring to a comprehensive epilepsy center for evaluation. Where you may use your limited time and capital with patients to counsel them on surgical treatments. Where a healthcare system with limited resources prioritizes patients. So, there's a significant need for having prediction tools that only take the input that a general neurologist seeing a patient in the clinic would have at hand. You know, the history, an MRI, an interictal EEG. Dr Monteith: I guess part of that prediction model includes adverse outcomes that you're communicating as well. Dr Friedman: Certainly, for me, when I'm discussing surgery for the patient in front of me, I will use prediction models for adverse outcomes as well that are informed by the kind of surgery we're proposing to do, especially when talking about things like language dysfunction and memory dysfunction after surgery. Dr Monteith: So, you mentioned a lot of great advances, and certainly since I was a resident, which wasn't that long ago. Why don't you tell me how some of these interventions have changed your clinical practice? Dr Friedman: Thinking about epilepsy surgery, like other surgical specialties, there's been a move to more minimally invasive approaches. For instance, when I started as an epilepsy fellow fifteen years ago, sixteen years ago, most of our surgeries involve removing a large portion of the skull, putting electrodes on the brain, doing resections through big craniotomies which were uncomfortable and risky, things like that. We now do our phase two or intracranial EEG monitoring through small burr holes in the brain using robotically placed electrodes. For many of our patients, we can actually treat their epileptic focus with a laser that is targeted through a small catheter and MRI guidance. And patients are usually home in two days with, you know, a lot less discomfort. Dr Monteith: Well, that's great. I didn't expect that one, but I do think that translates to many areas of neurology. Really just this idea of meeting their goals and personalizing their care. My last question is, what out of these advances and what you know about the future of epilepsy, what makes you the most excited and what gives you the most hope? Dr Friedman: I think there are a lot of exciting things in epilepsy. Last count I heard, there's something like over a hundred biotech companies developing epilepsy therapies. So that gives me hope that people are still interested in meeting the unmet needs of patients with epilepsy. And some of these therapies are really novel. For instance, there's a trial of stem cell treatments for drug-resistant temporal lobe epilepsy that's ongoing now, where inhibitory interneuron progenitor cells are implanted in the brain and kind of restore the brain circuit disruptions that we see in some of these epilepsies. There are combinations of drug and device therapies or gene therapy and device therapies that are in development, which have a lot of promise, and I think we'll have much more precise and targeted therapies within the next decade. Dr Monteith: Awesome. I really appreciate our conversation, and thank you so much for your wonderful article. I learned a lot reading it. Dr Friedman: Thank you. Dr Monteith: Today I've been interviewing Dr Daniel Friedman, whose article on surgical treatments, devices, tools, and non-medication management of epilepsy appears in the most recent issue of Continuum on epilepsy. Be sure to check out Continuum audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshmae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

 Are you experiencing unexplained fatigue, decreased libido, or mood changes? These symptoms might be related to testosterone levels – yes, even in women. In this enlightening episode of AGE BETTER, NYU Langone Health's Dr. Margaret Nachtigall breaks down everything you need to know about testosterone's role in women's health.   About Our Guest  Dr. Margaret Nachtigall is a renowned Reproductive Endocrinologist at NYU Langone Health, specializing in women's hormonal health. With extensive experience in treating hormone-related conditions, Dr. Nachtigall brings clarity to this often misunderstood aspect of women's health.  Why This Episode Matters to You  If you're a woman experiencing:  - Unexplained fatigue or low energy  - Decreased sex drive  - Mood changes  - Difficulty maintaining muscle mass  - Brain fog or reduced mental clarity  This episode provides crucial information about how testosterone might be affecting these symptoms.  What You'll Learn  - The surprising truth about testosterone's role in women's bodies  - How and where testosterone is produced in women  - Why testosterone levels change with age and menopause  - The connection between testosterone and common symptoms  - Current treatment options and their availability  - What to consider before pursuing testosterone therapy  - How to discuss this topic with your healthcare provider  Connect and Share  Have questions about testosterone or other women's health topics you'd like us to cover? We want to hear from you! Reach out to agebetterpodcast@gmail.com and join the conversation about women's health and healthy aging.   About AGE BETTER  AGE BETTER is dedicated to providing you with expert insights and practical information to help you make informed decisions about your health. Join us each week as we explore crucial topics in women's health with leading medical experts.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Greg Katz, a cardiologist at NYU Langone Health, takes us through a comprehensive approach to preventing cardiovascular disease in a patient with multiple risk factors. Using a patient case, Dr. Katz explains how to balance lifestyle changes with medical interventions and the role of imaging in risk assessment. He also discusses advanced lipid testing including Apolipoprotein B (apoB) and lipoprotein(a) (Lp(a)), and the evolving use of medications like statins and GLP-1 agonists.

In this episode of Understanding Healthcare, I sit down with Dr. Adam Ratner, Professor of Pediatrics and Microbiology at NYU Grossman School of Medicine and Director of the Division of Pediatric Infectious Diseases at NYU Langone Health. We discuss his upcoming book Booster Shots: The Urgent Lessons of Measles and the Uncertain Future of Children's Health, the growing epidemic of vaccine hesitancy, and how to rebuild trust in science. Dr. Ratner also shares his thoughts on the ethical tensions between personal freedom and public health, the biggest infectious disease threats facing children globally, and what gives him hope for the future of healthcare.

The introduction is done by Dr. Steven Flanagan, Chairperson of the Department of Rehabilitation at NYU Langone Health.  Sara Cuccurullo MD is Professor and Chairman, Residency Program Director in the Department of Physical Medicine and Rehabilitation at Hackensack Meridian School of Medicine, Rutgers- Robert Wood Johnson Medical School; Medical Director, VP at JFK Johnson Rehabilitation Institute; and Physician in Chief of HMH Rehabilitation Care Transformation Services  Talya Flemming MD is Medical Director: Stroke Recovery Program, Post-COVID Rehabilitation Program, Aftercare Program ABMS, Brain Injury Medicine Certified JFK Johnson Rehabilitation Institute, Department of Physical Medicine and Rehabilitation Clinical Associate Professor, Rutgers Robert Wood Johnson Medical School Core Associate Professor, Hackensack Meridian School of Medicine. Part 2 Dr. Flemming described the functional results obtained from their intervention. They specifically chose the activity measure proposed for post-acute care, abbreviated as AM-PAC. It showed improvement over time and it allowed looking at specific subsections within rehabilitation, such as basic mobility, daily activity, and cognitive scores. An AM-PAC score is a recognized tool by Medicare used in multiple post-acute care settings. Dr. Cuccurullo indicated that according to an article published in 2011 in the journal Stroke, the all-cause mortality for stroke patients in the U.S. is 31%. In one year, the all-cause mortality in their program was 1.47%. Their results were published in the American Journal of Physical Medicine and Rehabilitation. The paper received the Excellence in Research Writing Award for the most impactful article of the year. Significantly, the manuscript attracted the attention of Medicare officials who asked them to present their findings. CMS wanted to know if it can be proved that the stroke recovery program saves money, can they validate their previous improvement in mortality with more patients, and can they replicate the results at other institutions nationally. Drs. Fleming and Cuccurullo described what they did in response to these questions. A Question & Answer period followed.

 About This Episode  In this eye-opening discussion, Dr. Chiara Giannarelli breaks down the complex relationship between inflammation and aging, revealing how this hidden process impacts everything from heart health to our DNA. Whether you're in your 50s, 60s, or beyond, you'll discover practical steps to take control of your aging journey.  What You'll Learn  - The science behind inflammaging and why it accelerates after 50  - Critical blood markers to discuss with your doctor  - How COVID-19 affects long-term cardiovascular health  - The truth about "zombie cells" and their role in aging  - Practical strategies to reduce inflammation through lifestyle changes  - Emerging treatments that could revolutionize how we age  Key Takeaways  1. Inflammation isn't always harmful—it's when it becomes chronic that problems arise  2. Regular monitoring of specific blood markers is crucial after 50  3. The Mediterranean diet remains one of the most effective ways to combat inflammation  4. Sleep quality and stress management play vital roles in controlling inflammation  5. Simple lifestyle changes can significantly impact your inflammatory levels  Learn More About Dr. Giannarelli  Dr. Chiara Giannarelli is an Associate Professor in the Division of Cardiology and Department of Pathology at NYU Langone Health. Her groundbreaking research uses advanced single-cell technologies to study atherosclerosis and inflammation.   - Profile is HERE  - Latest Publications are HERE  - Lab Website is HERE    Have questions about this episode?   Email us at agebetterpodcast@gmail.com  Learn more about your ad choices. Visit megaphone.fm/adchoices

The introduction is done by Dr. Steven Flanagan, Chairperson of the Department of Rehabilitation at NYU Langone Health. Sara Cuccurullo MD is Professor and Chairman, Residency Program Director in the Department of Physical Medicine and Rehabilitation at Hackensack Meridian School of Medicine, Rutgers- Robert Wood Johnson Medical School; Medical Director, VP at JFK Johnson Rehabilitation Institute; and Physician in Chief of HMH Rehabilitation Care Transformation Services  Talya Flemming MD is Medical Director: Stroke Recovery Program, Post-COVID Rehabilitation Program, Aftercare Program ABMS, Brain Injury Medicine Certified JFK Johnson Rehabilitation Institute, Department of Physical Medicine and Rehabilitation Clinical Associate Professor, Rutgers Robert Wood Johnson Medical School Core Associate Professor, Hackensack Meridian School of Medicine. Part 1 Dr. Cuccurullo began by discussing their stroke recovery program, specifically investigating and analyzing the effects of a comprehensive initiative on all-cause mortality, function, and readmissions. She listed the learning objectives for today's grand round presentation. Strokes are the number one admission in their inpatient rehab facility. Twenty-two percent of their patients comply with going to the facility. Their patients have a finite resource for Medicare once they leave inpatient or the acute care setting. Payment caps compromise the ability to have outpatient therapies that prevent them from having a full recovery. Dr. Flemming pointed out that there is an overlap with patients who have neurologic disease after stroke as well as patients who have cardiac disease. So, they designed their program to combine both elements of neurorehabilitation and a modified cardiac rehabilitation program, which starts with an outpatient visit with a stroke physiatrist. Common challenges that need to be addressed are patients with: weakness on their one side versus the other, cognitive or attention deficits, poor safety awareness, and post-stroke fatigue. They decided that it would be important to collect medical and functional outcome data to see if the program could affect hospital readmissions, the recurrence of stroke, and overall mortality.

In this episode of 'Hot for Your Health,' Dr. Vonda Wright is joined by Dr. Sue Varma, MD, DFAPA, a renowned psychiatrist, cognitive behavioral therapist, and Clinical Assistant Professor of Psychiatry at NYU Langone Health. With over two decades of expertise, Dr. Varma is a trailblazer in mental health advocacy, serving as the first medical director of NYU's 9/11 mental health program and a trusted voice on national media platforms. Her upcoming book, Practical Optimism: The Art, Science, and Practice of Exceptional Wellbeing, is set to inspire readers worldwide in early 2024. In this episode, Dr. Varma dives into the long-term mental health effects of 9/11, exploring how trauma reshapes safety, trust, and community morale. She discusses the concept of post-traumatic growth and how finding meaning in adversity can fundamentally transform individuals. Dr. Varma also introduces the idea of "practical optimism," an approach that demonstrates how optimism can improve physical and mental health, boost longevity, and reduce the risk of major illnesses. The conversation highlights the balance between purpose, service, and self-care, incorporating insights from the Japanese concept of ikigai. Dr. Varma offers tools for processing emotions and shares how embracing self-compassion and rest can help individuals build resilience. This episode is packed with actionable advice on moving beyond survival to thriving and cultivating purpose and joy in daily life. Don't miss this empowering discussion! ••• Connect with Sue Varma: Instagram: @doctorsuevarma Website: www.doctorsuevarma.com Pre-order her book: doctorsuevarma.com/book ••• Make sure to follow Dr. Vonda Wright: Instagram: @drvondawright Youtube: https://www.youtube.com/@vondawright Tiktok: https://www.tiktok.com/@drvondawright LinkedIn: https://www.linkedin.com/in/vonda-wright-md-ms-2803374 Website: http://www.DrVondaWright.com ••• If you enjoyed this episode, Subscribe to “HOT For Your Health” for more inspiring episodes. Apple Podcast: https://podcasts.apple.com/us/podcast/hot-for-your-health/id1055206993 Spotify: https://open.spotify.com/show/1Q2Al27D79jCLAyzp4hKBv?si=b62b374994884eed We'd love to hear your thoughts on this episode! Share your comments or join the discussion on social media using #HotForYourHealthPodcast.

Catherine Parkin serves as Clinical Assistant Professor, Department of Rehabilitation Medicine at NYU Grossman School of Medicine, She co-authored the book, Medical aspects of disability for the rehabilitation professionals in 2017 by the Springer Publishing Company. Mary Regina Reilly has served as the Clinical Director of Speech Language Pathology at Rusk Rehabilitation, NYU Langue Health for the last ten years.  Her Master's Degree is from Columbia University and she did her fellowship at Montefiore Medical Center in the Bronx, New York.  Clinical concentration has focused on pediatric dysphagia with medically complex infants with additional efforts in developing specialty programs for adults with acquired neurogenic disorders. She was instrumental in assisting in the development of the Masters of Science Program in Communication Sciences at Yeshiva University and has served as an adjunct professor at both Mercy College and NYU Steinhardt. Dr. Angela Stolfi is the Director of Physical Therapy, Director of Therapy Services at Rusk Ambulatory Satellite Locations, Site Coordinator of PT Clinical Education, and Director of PT Residency and Fellowship Programs at Rusk Rehabilitation, NYU Langone Health.  Dr. Stolfi holds a faculty appointment in the Department of Rehabilitation at NYU School of Medicine and regularly lectures in the physical therapy programs at both NYU and the University of Scranton. The focus of much of her current and recent research relates to mentoring and education of student physical therapists.  She is also an Associate Editor of the Journal of Clinical Education in Physical Therapy (JCEPT). Maria Cristina Tafurt is the Site Director at the Rusk Institute NYU Langone Medical Center, Hospital for Joint Diseases.  She has been a licensed occupational therapist for over 30 years receiving her Bachelor's degree from the University of Rosario in Bogata Colombia, and her Advance Master's degree from NYU University.  Her clinical experience has varied with an emphasis on brain injury rehabilitation, pain management, hand therapy, and orthopedics. She holds a faculty appointment in the Department of Rehabilitation Medicine as a Clinical Instructor and has authored or co-authored sixteen articles, abstracts and international presentations in her field.  The discussion covered the following topics: influence of artificial intelligence, and research endeavors pertaining to occupational therapy, physical therapy, and speech-language pathology.

Catherine Parkin serves as Clinical Assistant Professor, Department of Rehabilitation Medicine at NYU Grossman School of Medicine, She co-authored the book, Medical aspects of disability for the rehabilitation professionals in 2017 by the Springer Publishing Company. Mary Regina Reilly has served as the Clinical Director of Speech Language Pathology at Rusk Rehabilitation, NYU Langue Health for the last ten years.  Her Master's Degree is from Columbia University and she did her fellowship at Montefiore Medical Center in the Bronx, New York.  Clinical concentration has focused on pediatric dysphagia with medically complex infants with additional efforts in developing specialty programs for adults with acquired neurogenic disorders. She was instrumental in assisting in the development of the Masters of Science Program in Communication Sciences at Yeshiva University and has served as an adjunct professor at both Mercy College and NYU Steinhardt. Dr. Angela Stolfi is the Director of Physical Therapy, Director of Therapy Services at Rusk Ambulatory Satellite Locations, Site Coordinator of PT Clinical Education, and Director of PT Residency and Fellowship Programs at Rusk Rehabilitation, NYU Langone Health.  Dr. Stolfi holds a faculty appointment in the Department of Rehabilitation at NYU School of Medicine and regularly lectures in the physical therapy programs at both NYU and the University of Scranton. The focus of much of her current and recent research relates to mentoring and education of student physical therapists.  She is also an Associate Editor of the Journal of Clinical Education in Physical Therapy (JCEPT). Maria Cristina Tafurt is the Site Director at the Rusk Institute NYU Langone Medical Center, Hospital for Joint Diseases.  She has been a licensed occupational therapist for over 30 years receiving her Bachelor's degree from the University of Rosario in Bogata Colombia, and her Advance Master's degree from NYU University.  Her clinical experience has varied with an emphasis on brain injury rehabilitation, pain management, hand therapy, and orthopedics. She holds a faculty appointment in the Department of Rehabilitation Medicine as a Clinical Instructor and has authored or co-authored sixteen articles, abstracts and international presentations in her field. The discussion covered the following topics: involvement of informal caregivers in treatment, staying on top of new developments, use of assistive technology, provision of care via telehealth, and impact of Long Covid on patient care.

In this episode of Genetics in Your World, GSA Early Career Scientist Multimedia Subcommittee member Sarah Gilmour has a conversation with Dr. Guðjón Ólafsson of NYU Langone Health and University of Iceland about his attempts to “humanize” the yeast kinetochore and how the difficulties of doing so teach us about the evolution of essential kinetochore proteins. Read Dr. Ólafsson's paper titled, “Humanization reveals pervasive incompatibility of yeast and human kinetochore components,” published in the January 2024 issue of G3: Genes|Genomes|Genetics: https://doi.org/10.1093/g3journal/jkad260. Music: Loopster Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 License, http://creativecommons.org/licenses/by/3.0/ Hosted on Acast. See acast.com/privacy for more information.

In this episode Dr. Geo sits down with Dr. Stacy Loeb, a leading prostate cancer researcher and faculty member at NYU Langone Health. Renowned for publishing more scientific papers on prostate cancer than any other woman in the field, Dr. Loeb shares her expertise on the benefits of plant-based diets in preventing and managing prostate cancer.Dr. Loeb, inspired by her grandfather's battle with prostate cancer, combines her groundbreaking research and board certification in Lifestyle Medicine to provide actionable tips for eating more plants and improving prostate health. Together, they discuss the science behind plant-based nutrition, the practical steps to implement these changes, and how lifestyle medicine can enhance overall quality of life.Whether you're seeking to prevent prostate cancer, manage a diagnosis, or simply live healthier, this episode is packed with insights to help you take control of your health.Key Takeaways:Why plant-based diets can lower the risk of prostate cancer and improve quality of life.Simple, actionable tips to incorporate more plants into your diet.The critical role of lifestyle changes—nutrition, exercise, sleep, and stress management—in prostate cancer prevention and care.How Dr. Loeb's personal journey and innovative research continue to transform the field of integrative urology.----------------Thank you to our partners.This episode is also brought to you by AG1 (Athletic Greens). AG1 contains 75 high-quality vitamins, minerals, whole-food sourced ingredients, probiotics, and adaptogens to help you start your day right. This special blend of ingredients supports your gut health, nervous system, immune system, energy, recovery, focus, and aging. All the things. Enjoy AG1 (Athletic Greens).----------------

Catherine Parkin serves as Clinical Assistant Professor, Department of Rehabilitation Medicine at NYU Grossman School of Medicine, She co-authored the book, Medical aspects of disability for the rehabilitation professionals in 2017 by the Springer Publishing Company. Mary Regina Reilly has served as the Clinical Director of Speech Language Pathology at Rusk Rehabilitation, NYU Langue Health for the last ten years.  Her Master's Degree is from Columbia University and she did her fellowship at Montefiore Medical Center in the Bronx, New York.  Clinical concentration has focused on pediatric dysphagia with medically complex infants with additional efforts in developing specialty programs for adults with acquired neurogenic disorders. She was instrumental in assisting in the development of the Masters of Science Program in Communication Sciences at Yeshiva University and has served as an adjunct professor at both Mercy College and NYU Steinhardt. Dr. Angela Stolfi is the Director of Physical Therapy, Director of Therapy Services at Rusk Ambulatory Satellite Locations, Site Coordinator of PT Clinical Education, and Director of PT Residency and Fellowship Programs at Rusk Rehabilitation, NYU Langone Health.  Dr. Stolfi holds a faculty appointment in the Department of Rehabilitation at NYU School of Medicine and regularly lectures in the physical therapy programs at both NYU and the University of Scranton. The focus of much of her current and recent research relates to mentoring and education of student physical therapists.  She is also an Associate Editor of the Journal of Clinical Education in Physical Therapy (JCEPT). Maria Cristina Tafurt is the Site Director at the Rusk Institute NYU Langone Medical Center, Hospital for Joint Diseases.  She has been a licensed occupational therapist for over 30 years receiving her Bachelor's degree from the University of Rosario in Bogata Colombia, and her Advance Master's degree from NYU University.  Her clinical experience has varied with an emphasis on brain injury rehabilitation, pain management, hand therapy, and orthopedics. She holds a faculty appointment in the Department of Rehabilitation Medicine as a Clinical Instructor and has authored or co-authored sixteen articles, abstracts and international presentations in her field. The discussion in Part Two covered the following topics: types of patients treated, impact of health care disparities, and patient cooperation in health care interventions by providers.

On this episode, we are joined by April O'Connell to discuss exercise dosing for patients who have sustained injuries of their upper extremity. She shares with us factors that should be considered when designing an exercise program for a patient and how to progress them through their plan of care to achieve their goals and beyond. Guest Bio: April O'Connell, OTR/L, CHT, ACSM, is an occupational therapist at Cedars Sinai Hospital in Beverly Hills, CA. She works with a variety of sports teams including the NFL, MLB and NBA and recently spoke at ASHT and AAHT on Rehabilitation of the Overhead Athlete. She is one of the main contributors to the fellowship program for hand and upper extremity rehabilitation as well as the co-director for Cedars Sinai Hand Symposium. April got her start as the Clinical Specialist in the Hand and Upper Extremity Therapy Department at NYU Langone Health. She has lectured to orthopedic surgeons and therapists nationally and internationally in current concepts of orthopedic rehabilitation of the upper extremity. Some of her most recent lectures include being a guest speaker for Dr. Radio on Sirius Satellite on topics for rehabilitation of the hand and upper extremity as well as injuries to the overhead athlete. In addition, she has presented on Flexor Tendon Repair Advancement at AAOS in 2015 and was later asked to speak at the ASSH national conference in 2016 and ASHT in 2017. She recently presented her latest research at the ASHT National Conference on flexor tendon rehabilitation in 2019. April is a founding member of the NYU Langone Golf and Pitching Labs and was the head hand therapist for the first successful bilateral hand and face allotransplantation. She earned her Occupational Therapy degree at Boston University, is a Certified Hand Therapist and is certified by the American Council of Sports Medicine (ACSM) as a Clinical Exercise Specialist.

In this episode of the Dr. Geo Podcast, Dr. Geo concludes a four-week exploration of treatments for benign prostate hyperplasia (BPH) with a focus on Aquablation Therapy, an innovative robotic, heat-free treatment using water jet technology to address urinary issues caused by an enlarged prostate. Dr. Geo welcomes Dr. Chris Kelly, a urologist at NYU Langone Health and an expert in Aquablation, to share insights on this groundbreaking procedure.Dr. Kelly delves into the benefits of Aquablation compared to traditional treatments such as TURP (transurethral resection of the prostate) and other minimally invasive options. Key topics include the science behind Aquablation, its ability to personalize treatment based on prostate size and shape, and its superior outcomes in preserving sexual function, especially ejaculation. The conversation also covers how Aquablation offers a faster recovery time and lower retreatment rates than other surgical options.Key Points:Differentiating urinary symptoms caused by BPH, prostatitis, or overactive bladder.The role of diagnostic tools like urodynamic studies and post-void residual tests.Factors influencing the choice of surgical treatments for BPH, including prostate size, bladder function, and patient goals.Clinical evidence supporting Aquablation's safety and effectiveness, including studies showing its long-term benefits.Dr. Kelly shares his experience with over 150 successful Aquablation procedures and provides practical advice for patients considering this therapy. Whether you're exploring treatment options for BPH or interested in advancements in urology, this episode offers a wealth of actionable information.Don't miss this in-depth discussion on a revolutionary approach to treating BPH.

Vaping and vein health! Covid and clots! Easy bruising! Movie blood! Spider veins! Free socks! The heroic vascular surgeon Dr. Sheila Blumberg of NYU Langone Health let me ask her one million questions about how blood gets from point A to B all day. She explains the difference between arteries, veins, capillaries, and vessels and we cover everything from fainting to teenage movie tropes, how to tie a tourniquet, atherosclerosis, aneurysms, stents and why your leg is asleep right now. View Dr. Blumberg's publications on ResearchGateA donation went to BreakingGround.orgMore episode sources and linksSmologies (short, classroom-safe) episodesOther episodes you may enjoy: Diabetology (BLOOD SUGAR), Field Trip: My Butt, Colonoscopy Ride Along, Functional Morphology (ANATOMY), Hematology (BLOOD), Surgical Oncology (BREAST CANCER), Biogerontology (AGING), Proptology (THEATER & FILM PROPS), Vampirology (VAMPIRES)Sponsors of OlogiesTranscripts and bleeped episodesBecome a patron of Ologies for as little as a buck a monthOlogiesMerch.com has hats, shirts, hoodies, totes!Follow Ologies on Instagram and BlueskyFollow Alie Ward on Instagram and TikTokEditing by Mercedes Maitland of Maitland Audio Productions and Jake ChaffeeManaging Director: Susan HaleScheduling Producer: Noel DilworthTranscripts by Aveline Malek Website by Kelly R. DwyerTheme song by Nick Thorburn

Catherine Parkin serves as Clinical Assistant Professor, Department of Rehabilitation Medicine at NYU Grossman School of Medicine, She co-authored the book, Medical aspects of disability for the rehabilitation professionals in 2017 by the Springer Publishing Company. Mary Regina Reilly has served as the Clinical Director of Speech Language Pathology at Rusk Rehabilitation, NYU Langue Health for the last ten years.  Her Master's Degree is from Columbia University and she did her fellowship at Montefiore Medical Center in the Bronx, New York.  Clinical concentration has focused on pediatric dysphagia with medically complex infants with additional efforts in developing specialty programs for adults with acquired neurogenic disorders. She was instrumental in assisting in the development of the Masters of Science Program in Communication Sciences at Yeshiva University and has served as an adjunct professor at both Mercy College and NYU Steinhardt. Dr. Angela Stolfi is the Director of Physical Therapy, Director of Therapy Services at Rusk Ambulatory Satellite Locations, Site Coordinator of PT Clinical Education, and Director of PT Residency and Fellowship Programs at Rusk Rehabilitation, NYU Langone Health.  Dr. Stolfi holds a faculty appointment in the Department of Rehabilitation at NYU School of Medicine and regularly lectures in the physical therapy programs at both NYU and the University of Scranton. The focus of much of her current and recent research relates to mentoring and education of student physical therapists.  She is also an Associate Editor of the Journal of Clinical Education in Physical Therapy (JCEPT). Maria Cristina Tafurt is the Site Director at the Rusk Institute NYU Langone Medical Center, Hospital for Joint Diseases.  She has been a licensed occupational therapist for over 30 years receiving her Bachelor's degree from the University of Rosario in Bogata Colombia, and her Advance Master's degree from NYU University.  Her clinical experience has varied with an emphasis on brain injury rehabilitation, pain management, hand therapy, and orthopedics. She holds a faculty appointment in the Department of Rehabilitation Medicine as a Clinical Instructor and has authored or co-authored sixteen articles, abstracts and international presentations in her field. The discussion covered the following topics in Part One: a description of each of the three professions, educational requirements to become practitioners, and recruitment and retention of clinicians. 

 In this episode of Age Better, host Barbara Hannah Grufferman is joined by Dr. Margaret Nachtigall, a reproductive endocrinologist at NYU Langone Health, to discuss the critical link between metabolic syndrome and dementia, particularly in midlife women. They delve into what metabolic syndrome is, why it's so common, and the latest research that underscores a significant increase in the risk of developing dementia for those with this condition. The episode highlights the crucial role of lifestyle changes, such as adopting healthy eating habits, engaging in regular exercise, and avoiding smoking and excessive alcohol consumption, to lower risks and support brain health as we age.    KEY TAKEAWAYS:   - Metabolic syndrome comprises a combination of factors, including insulin resistance.  - Post-menopausal women are more prone to metabolic syndrome due to decreased estrogen levels.  - Having metabolic syndrome elevates the risk of developing dementia.  - Recent research shows a 7% increase in dementia risk for individuals with metabolic syndrome.  - Lifestyle elements like smoking, inactivity, and poor sleep contribute to metabolic syndrome.  - Healthy eating and consistent exercise are key preventative measures.  - There is no safe level of alcohol consumption for optimal health.  - Even brief periods of exercise can have a substantial positive impact.  - Maintaining healthy habits is essential to avoiding metabolic syndrome.  - A healthy lifestyle not only reduces disease risk but also enhances overall happiness and well-being.    LINKS TO LEARN MORE:  Read more about the connection between metabolic syndrome and dementia here.    Listen to the episode of AGE BETTER discussing how HIIT can lower risks for metabolic syndrome here.    LEARN MORE ABOUT AGE BETTER PODCAST:   Age Better podcast delves into a diverse range of topics, including finance, work, health, fitness, style, makeup, hair, nutrition, travel, relationships, sex, menopause and more. Each week, I'll bring you the latest insights, expert opinions, and actionable advice.   LISTEN AND SUBSCRIBE!  To join this adventure, remember to subscribe or follow the "Age Better with Barbara Hannah Grufferman" podcast on platforms like Apple Podcasts, Spotify, and YouTube. Yep, you can watch it or just listen!  Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Heidi Fusco is an assistant professor of Rehabilitation Medicine at NYU LANGONE Health and the Rusk Rehabilitation hospital. She is the Assistant Director of the Traumatic Brain Injury Program at Rusk and the Medical Director of the Brain Injury Unit at Queens Nassau Nursing and Rehabilitation. She completed a fellowship in Brain injury Rehab in 2013 at the Rusk Institute and is board certified in Brain Injury medicine and Physical Medicine and Rehabilitation. Alaina B. Hammond is a board certified rehabilitation psychologist and currently serves as Clinical Assistant Professor and Staff Psychologist in the NYU Langone Rusk Adult Inpatient - Brain Injury Rehabilitation Program.  She provides psychological and neuropsychological intervention and assessment to patients and families with acquired brain injury, stroke, spinal cord injury and other illness/injuries. In addition, she supervises psychology interns and enjoys researching family/caregiver adjustment to medical illness.  Dr. Jessica Rivetz is the current Brain Injury Medicine Fellow at NYU Rusk Rehabilitation. She recently completed her residency in physical medicine and rehabilitation at NYU Rusk. She received her MD degree at Albany Medical College, and also has a Master's of Science in health care management. Extracurricular activities include serving as co-chairperson of the NYU GME House Staff Patient Safety Council. Within brain injury medicine, she has a special interest managing patients with moderate to severe traumatic brain injury and helping them and their caregivers navigate life after brain injury and achieve their functional and quality of life goals. Part 3 The discussion covered the following topics: phases of treatment when mindfulness and self-compassion can be introduced to achieve optimal effectiveness; the role of telehealth; extent to which a group-based approach is used; availability of commercialized digital resources on the Internet, such as apps; use of wearable devices by patients; and the impact of artificial intelligence on patient care.  

Dr. Heidi Fusco is an assistant professor of Rehabilitation Medicine at NYU LANGONE Health and the Rusk Rehabilitation hospital. She is the Assistant Director of the Traumatic Brain Injury Program at Rusk and the Medical Director of the Brain Injury Unit at Queens Nassau Nursing and Rehabilitation. She completed a fellowship in Brain injury Rehab in 2013 at the Rusk Institute and is board certified in Brain Injury medicine and Physical Medicine and Rehabilitation. Alaina B. Hammond is a board certified rehabilitation psychologist and currently serves as Clinical Assistant Professor and Staff Psychologist in the NYU Langone Rusk Adult Inpatient - Brain Injury Rehabilitation Program.  She provides psychological and neuropsychological intervention and assessment to patients and families with acquired brain injury, stroke, spinal cord injury and other illness/injuries. In addition, she supervises psychology interns and enjoys researching family/caregiver adjustment to medical illness.  Dr. Jessica Rivetz is the current Brain Injury Medicine Fellow at NYU Rusk Rehabilitation. She recently completed her residency in physical medicine and rehabilitation at NYU Rusk. She received her MD degree at Albany Medical College, and also has a Master's of Science in health care management. Extracurricular activities include serving as co-chairperson of the NYU GME House Staff Patient Safety Council. Within brain injury medicine, she has a special interest managing patients with moderate to severe traumatic brain injury and helping them and their caregivers navigate life after brain injury and achieve their functional and quality of life goals. Part 2 The discussion covered the following topics: persistence of sleep disorders and the role of physical exercise in treating them; definition of mindfulness; kinds of interventions included under the heading of mindfulness; examples of how it aims to address the severity of various TBI-related health problems; duration of mindfulness treatment; and self-compassion as another type of non-pharmacological intervention.

Welcome to another episode of AGE BETTER!    If you've ever wondered about the impact of hearing loss or have been hesitant to explore hearing aids, this episode is for you. With approximately 30 million Americans potentially benefiting from hearing aids and the majority not using them, it's clear that traditional solutions aren't meeting people's needs. That's where Apple's latest innovation comes in—transforming their popular AirPods Pro 2 into over-the-counter hearing aids with just a software update. This breakthrough could be a game-changer for millions.    In this conversation, Dr. Nicholas Reed from NYU Langone Health's Optimal Aging Institute explains why this development is so significant. We'll explore the barriers people face when it comes to addressing hearing loss, such as stigma and cost, and how technology can bridge the gap. You'll also learn about the broader implications of wearable tech in healthcare and why regular hearing tests are more important than ever, especially as we age.    WHAT YOU'LL LEARN FROM THIS EPISODE    The Impact of Mild to Moderate Hearing Loss: Discover how even slight hearing impairment can significantly affect quality of life, contributing to issues like depression, cognitive decline, and social isolation.  Overcoming the Stigma: Learn how Apple's AirPods, with their mainstream appeal and affordable pricing, could help reduce the stigma often associated with traditional hearing aids.  The Role of Technology in Hearing Health: Understand how advancements in wearable technology are transforming healthcare, making it more accessible and integrated into our daily lives.  The Importance of Regular Hearing Tests: Find out why Dr. Reed recommends regular hearing tests for everyone, and how Apple's new feature allows you to check your hearing at home using just an iPhone or iPad.  Holistic Health and Aging: Hear about the Optimal Aging Institute's holistic approach to health and how it addresses the unique challenges of aging, including hearing health.    KEY LINKS FOR MORE INFORMATION  Learn more about Dr. Nicholas Reed HERE.  Find out more about NYU Langone Health's Optimal Aging Institute HERE.   Learn more about TUNED: Hearing Telehealth HERE.       LEARN MORE ABOUT AGE BETTER PODCAST      Age Better podcast delves into a diverse range of topics, including finance, work, health, fitness, style, makeup, hair, nutrition, travel, relationships, sex, menopause and more. Each week, I'll bring you the latest insights, expert opinions, and actionable advice.          Listen and Subscribe        To join this adventure, remember to subscribe or follow the "Age Better with Barbara Hannah Grufferman" podcast on platforms like Apple Podcasts, Spotify, and YouTube. Yep, you can watch it or just listen!      Learn more about your ad choices. Visit megaphone.fm/adchoices

Ever felt like your bathroom breaks are more frequent than they used to be? Or maybe you've noticed a change in your sex life? It might be time to pay attention to your prostate.Join me and Dr. Geo Espinosa as he reveals the hidden link between BPH and erectile dysfunction—two issues that often go hand-in-hand. Discover why prostate health is crucial for both your urinary and sexual well-being. Plus, learn about natural solutions that could help you avoid medications and side effects.Don't let prostate problems steal your quality of life. Tune in now to get the information you need to take control of your health.--------------About Dr. Geo EspinosaDr. Geo Espinosa is a leading naturopathic functional medicine doctor specializing in urology and men's health. With expertise in prostate cancer, benign prostatic hyperplasia (BPH), and male sexual dysfunction, Dr. Geo holds faculty positions at NYU Langone Health and the Institute for Functional Medicine. As the Chief Medical Officer of XY Wellness and a co-founder of DrGeo.com, he is dedicated to providing integrative and holistic approaches to men's health. Dr. Geo is also the author of the best-selling book Thrive, Don't Only Survive on prostate cancer.Connect with Dr. GeoStay connected with Dr. Geo for the latest insights on men's health and prostate care! Follow him on Instagram @drgeond, subscribe to his YouTube channel here, and visit his website at drgeo.com.--------------If you liked this episode, please SUBSCRIBE, like, leave a comment, and share so we can keep bringing you valuable content that gets results!--------------Follow Me On:InstagramTwitterFacebookTikTokYouTube--------------For all links and resources mentioned on the show and where to subscribe to the podcast, please visit https://sexualhealthformenpodcast.com/prostate-health-tips--------------Ready to empower your health journey? Secure your FREE PDF copy of the “5 Natural Solutions to Overcome ED” today! Dive into knowledge that could transform your life. Click the link below to claim your copy

If you're thinking about going vegan as a family, or you're already vegan and expecting a wee one and wanting to raise them vegan, this is the episode for you! As a plant-based dietitian and mom of 2, this is an episode I've been meaning to do for a while! There is a lot of misinformation about feeding kids a vegan diet…and a weird amount of negative headlines that have been attributed to vegan eating that were really parents not feeding their kids properly. So I'm super excited to be chatting with registered dietitian Karla Moreno-Bryce RD, who focuses specifically on vegan pediatric nutrition, all about how to feed vegan kids well. The reality of fostering healthy growth and development isn't all that different, whether your children are omnivores, vegetarian or vegan. Kids have specific nutrient needs, like protein or calcium, and you simply need to ensure that you are offering foods rich in those nutrients! So in this episode, we get into specifics about nutrients of concern and which foods and supplements are essential for meeting their needs. It will help you get clearer on how to plan your family meals so that your kids thrive on a plant-based diet.About Karla: Karla Moreno-Bryce, MDA, RD, LD is a leading expert in pediatric vegan nutrition, author of the Vegan Kids Cookbook, and mom of two vegan girls. She has worked with hundreds of committed vegan parents from all around the world to help them feel confident feeding their kids a vegan diet for proper growth and development. Her insights have been featured in highly recognized outlets like Huffpost, BBC, and National Geographic and has been a speaker at the Vegan Women Summit, Twin Cities Veg Fest, and NYU Langone Health. In her spare time, she enjoys having picnics with her family—unless it's in the middle of Winter in Minnesota.  On this episode we chat about: Is it possible to raise healthy vegan kids? Going vegan as a family Which nutrients do we need to watch most for vegan kids? Talking about iron-fortified cereals: yay or nay? The one important mineral that no one talks about for vegans  How much protein do kids need? The best plant-based milk for kids How to navigate high fibre foods with little tummies Making sure kids get enough energy for growth What supplements do vegan kids need? Navigating the family meal Support the Pod! We couldn't make this podcast happen without the support of our amazing listeners… I love hearing your feedback on these episodes to be sure to join the conversation on our instagram @theallsortspod @desireenielsenrd @vegan.kids.nutrition If you love this episode, please share it with your friends and family, or take a minute to rate, review or subscribe on your favourite podcast app. We appreciate EVERY. SINGLE. LISTEN! recommendations

Dr. Heidi Fusco is an assistant professor of Rehabilitation Medicine at NYU LANGONE Health and the Rusk Rehabilitation hospital. She is the Assistant Director of the Traumatic Brain Injury Program at Rusk and the Medical Director of the Brain Injury Unit at Queens Nassau Nursing and Rehabilitation. She completed a fellowship in Brain injury Rehab in 2013 at the Rusk Institute and is board certified in Brain Injury medicine and Physical Medicine and Rehabilitation. Alaina B. Hammond is a board certified rehabilitation psychologist and currently serves as Clinical Assistant Professor and Staff Psychologist in the NYU Langone Rusk Adult Inpatient - Brain Injury Rehabilitation Program.  She provides psychological and neuropsychological intervention and assessment to patients and families with acquired brain injury, stroke, spinal cord injury and other illness/injuries. In addition, she supervises psychology interns and enjoys researching family/caregiver adjustment to medical illness.  Dr. Jessica Rivetz is the current Brain Injury Medicine Fellow at NYU Rusk Rehabilitation. She recently completed her residency in physical medicine and rehabilitation at NYU Rusk. She received her MD degree at Albany Medical College, and also has a Master's of Science in health care management. Extracurricular activities include serving as co-chairperson of the NYU GME House Staff Patient Safety Council. Within brain injury medicine, she has a special interest managing patients with moderate to severe traumatic brain injury and helping them and their caregivers navigate life after brain injury and achieve their functional and quality of life goals. Part 1 The discussion covered the following topics: concussions and TBIs; pediatric care; use of biomarkers; common causes of a TBI; common symptoms and their length of duration; involvement of informal caregivers; and occurrence of sleep disorders.

Get caught up on prostate artery embolization (PAE) best practices and learn the ins-and-outs of building a PAE program in 2024. Dr. Jason Hoffmann covers this and more, with host Dr. Michael Barraza. Dr. Hoffmann is an interventional radiologist and educator at NYU Langone Health. --- CHECK OUT OUR SPONSOR Merit Biopsy Solutions https://www.merit.com/solutions/biopsy-solutions/ --- SYNPOSIS The doctors delve into strategies for developing expertise within a practice, coordinating with urologists, and effectively managing patient expectations. Dr. Hoffmann shares insights on leveraging different imaging techniques, equipment choices, and best practices for ensuring post-procedure patient satisfaction. The discussion also touches on the evolution of PAE guidelines, insurance challenges, and the importance of longitudinal care in interventional radiology. --- TIMESTAMPS 00:00 - Introduction 04:12 - Building a BPH Program and PAE Practice 06:28 - Referrals and Relationship with Urology 15:27 - Patient Workup and Setting Expectations 27:10 - SwiftNinja Study: Initial Impressions and Findings 31:43 - Patient Management and Post-Procedure Care 35:37 - Building a Successful PAE Practice 42:19 - Conclusion --- RESOURCES BackTable VI Podcast Episode #445 - Inside the IR Suite: A Clinician's Own Battle with Portal Vein Thrombosis with Dr. Jason Hoffmann: https://www.backtable.com/shows/vi/podcasts/445/inside-the-ir-suite-a-clinicians-own-battle-with-portal-vein-thrombosis AUA Guidelines on Benign Prostatic Hyperplasia (Updated 2023): https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-(bph)-guideline Use of a steerable microcatheter during superselective angiography: impact on radiation exposure and procedural efficiency: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966367/

"Patients who were on hormone therapy had a lower biologic age compared to the women who were not on hormone therapy." – Dr. Margaret Nachtigall    In this episode of AGE BETTER, we dive into a new and exciting study that suggests hormone therapy (HT) may help women not only feel better but also stay biologically younger. We're talking about a study that analyzed data from over 117,000 women and found that those on hormone therapy had a lower biologic age compared to those who weren't. The most significant benefits were seen in women who used hormone therapy for four to eight years, but as always, there's more to the story.     Our guest, Dr. Margaret Nachtigall, a menopause expert and reproductive endocrinologist at NYU Langone Health and Medical Director of Menopause Cheat Sheet, is here to break it all down for us. Together, we explore how hormone therapy can influence biological aging, the risks and benefits of HT, and why timing and duration are key. Whether you're considering hormone therapy or already on it, this episode is packed with insights to help you make informed decisions about your health.    KEY TAKEAWAYS  Hormone therapy can help women look and feel biologically younger: Women using hormone therapy showed a lower biological age compared to those who never used it, especially when used for 4-8 years.      The most benefits are seen in women who use hormone therapy for 4 to 8 years: A longer duration of hormone therapy within this window seems to be associated with the best outcomes in reducing biological age and improving overall health.      Risks like blood clots and breast cancer must be considered:  As with all medical treatments, HT isn't risk-free. Dr. Nachtigall explains how risks like blood clotting and breast cancer need to be weighed carefully and personalized for each individual.      The timing and duration of hormone therapy should be individualized:  Hormone therapy isn't one-size-fits-all, and Dr. Nachtigall emphasizes the importance of starting HT at the right time and determining the best duration for each woman.    WHY YOU SHOULD LISTEN TO THIS EPISODE:  You're in midlife and want to take control of your health: If you're navigating menopause or considering hormone therapy, this episode gives you the latest research and expert advice on how HT could benefit you.  You want to learn about new ways to age better: Dr. Nachtigall breaks down how hormone therapy could help you stay biologically younger, offering new insights on aging well.  You're already using hormone therapy and want to make sure it's the right choice: We discuss not only the benefits but also the risks, helping you make more informed decisions about your treatment.    KEY LINKS & RESOURCES:  - Learn more about hormone therapy and menopause: [Menopause Cheat Sheet]  - Read the study discussed in this episode: [JAMA Network Open] - Connect with Dr. Margaret Nachtigall: [NYU Langone Health]   FOLLOW & SUBSCRIBE  Be sure to subscribe to AGE BETTER with Barbara Hannah Grufferman for more conversations that help you take charge of your health and well-being as you age.  Learn more about your ad choices. Visit megaphone.fm/adchoices

The introduction is done by Dr. Steven Flanagan, Chairperson of the Department of Rehabilitation at NYU Langone Health. His remarks ended at the 2 minute: 24 second mark. Dr. Darryl Kaelin is the Endowed Chair of Stroke and Brain Injury Rehabilitation at the University of Louisville. In this Grand Rounds session, he speaks about Traumatic Brain Injury and its Association with Neurodegenerative Disorders. Part 1 Dr. Kaelin described the interesting relationship between the University of Louisville Frazier Rehabilitation Institute and NYU Rusk in New York. The Institute has its origins at NYU. His presentation had a focus on cellular level and pathophysiology that contribute to complications of brain injury, Alzheimer's type dementia, Parkinson's Disease and some similarities that exist. He began a literature review one-year ago on this topic, which has led to today's discussion. It is important to start by talking a little about the pathophysiology TBI and cerebral insults. It can have some correlation to stroke and other insults to the brain and central nervous system. He also talked a little bit about things that we don't think about much as physiatrists –astrocytes and microglia and what their roles are in the brain and in brain trauma. He indicated that astrocytes are the scaffolding or the structure upon which neurons and other cells hold themselves to and create the structure and shape of the brain. Microglial cells help in brain infection and brain inflammation. In a resting, healthy brain they are highly mobile and will undergo morphological changes following a brain trauma. He indicated that synapses between neurons are significantly affected both mechanically and in becoming lost in severe brain injury. He discussed the importance of sleep for patients with a brain injury. Part 2 Repetitive mild brain injuries also can result in the same kinds of findings. So, it is not just moderate to severe, but repetitive mild injuries that increase the risk. Although there may not be a direct causal relationship, certainly having a brain injury, multiple mild brain injuries or a moderate to severe brain injury increases the risk of developing neurodegenerative processes like Alzheimer's and Parkinson's.  He tells his patients that the likelihood of developing a neurodegenerative process may be there, but in each individual it can be different. We don't know specifically what it might mean for you. On average the risk may go up, but it still is very small. He talked about some potential neuro-protective treatments that might exist out there or are in the process of being looked at. He stated that this patient population is heavily heterogeneous, especially in how it presents and responds to trauma. Additionally, patients in the U.S. don't all receive exactly the same treatment after their trauma, which is a confounding variable that results in a very different outcome for each of those kinds of patients. Nutrition is a highly important factor when it comes to recovery and outcomes.  Parenteral nutrition goes a long way in helping their outcomes. It also is important to keep an eye on vitamin and mineral levels.  Zinc is a key supplement for many patients and magnesium can help in recovery. He closed by describing a disorders of consciousness program at his institution called the Emerge Program. A Question &Answer period followed.  

In this episode, hosts Drs. Peter Lu and Jennifer Lee talk to Dr. Kara Margolis about caring for autistic children with GI disorders. We discuss the relationship between autism and the GI tract, how GI disorders can present differently in autistic children, and ways to improve our clinical care for autistic children with GI disorders.Dr. Margolis is a pediatric gastroenterologist at NYU Langone Health, Associate Professor at the NYU Grossman School of Medicine, and Director of the NYU Pain Research Center. She is one of the leading physician scientists in the study of children with disorders of gut-brain interaction and their relationship with autism spectrum disorder.Learning Objectives:Recognize the relationship between autism spectrum disorder and the gastrointestinal tract.Understand ways to improve our clinical care for autistic children with GI disorders.Understand the current evidence (or lack of) for probiotic supplements and dietary treatment for autistic children with GI disorders.Links:Hung, L. Y., & Margolis, K. G. (2024). Autism spectrum disorders and the gastrointestinal tract: insights into mechanisms and clinical relevance. Nature reviews. Gastroenterology & hepatology, 21(3), 142–163.Buie, T., & Margolis, K. (2024). Considerations for treating autistic individuals in gastroenterology clinics. The lancet. Gastroenterology & hepatology, 9(8), 684–686.Colliderscope Podcast Episode: Kara Margolis on the Importance of Kindness in the LabSupport the Show.This episode is eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.